Quipt Home Medical Unveils Strategic Priorities for 2025 to Enhance Shareholder Value and Announces Voting Results from its Annual General Meeting
Quipt Home Medical Corp. (NASDAQ: QIPT) has announced its strategic priorities for 2025, focusing on enhancing shareholder value through multiple initiatives. The company plans to accelerate organic growth by expanding De Novo locations, following successful openings in Florida and Alabama, and deepening referral networks with healthcare providers.
Key strategic priorities include implementing a share repurchase program through Normal Course Issuer Bid (NCIB), reflecting confidence in the company's fundamentals. Quipt is also pursuing strategic M&A opportunities with healthcare systems through potential joint ventures and acquisitions, aiming to integrate home-based care within larger healthcare ecosystems.
The company is launching the Quipt Sales Accelerator program for advanced sales training and expanding its product portfolio with new respiratory offerings. At its Annual General Meeting, shareholders approved the re-appointment of BDO USA as auditor and elected four directors. The board approved grants of 425,000 stock options at US$2.37 per share and 2,478,753 restricted stock units under its 2024 Equity Incentive Plan.
Quipt Home Medical Corp. (NASDAQ: QIPT) ha annunciato le sue priorità strategiche per il 2025, concentrandosi sul miglioramento del valore per gli azionisti attraverso molteplici iniziative. L'azienda prevede di accelerare la crescita organica espandendo le sedi De Novo, dopo le aperture di successo in Florida e Alabama, e approfondendo le reti di riferimento con i fornitori di assistenza sanitaria.
Le principali priorità strategiche includono l'implementazione di un programma di riacquisto di azioni attraverso il Normal Course Issuer Bid (NCIB), a testimonianza della fiducia nei fondamentali dell'azienda. Quipt sta anche perseguendo opportunità strategiche di M&A con sistemi sanitari attraverso potenziali joint venture e acquisizioni, con l'obiettivo di integrare l'assistenza domiciliare all'interno di ecosistemi sanitari più ampi.
L'azienda sta lanciando il programma Quipt Sales Accelerator per una formazione avanzata alle vendite e sta ampliando il proprio portafoglio prodotti con nuove offerte respiratorie. Durante l'Assemblea Generale Annuale, gli azionisti hanno approvato il rinnovo dell'incarico di BDO USA come revisore dei conti ed eletto quattro direttori. Il consiglio ha approvato l'assegnazione di 425.000 opzioni su azioni a 2,37 USD per azione e 2.478.753 unità di azioni riservate nell'ambito del suo Piano di Incentivazione Azionaria 2024.
Quipt Home Medical Corp. (NASDAQ: QIPT) ha anunciado sus prioridades estratégicas para 2025, centrándose en mejorar el valor para los accionistas a través de múltiples iniciativas. La compañía planea acelerar el crecimiento orgánico expandiendo las ubicaciones De Novo, tras las exitosas aperturas en Florida y Alabama, y profundizando las redes de referencia con los proveedores de atención médica.
Las principales prioridades estratégicas incluyen la implementación de un programa de recompra de acciones a través del Normal Course Issuer Bid (NCIB), lo que refleja la confianza en los fundamentos de la compañía. Quipt también está buscando oportunidades estratégicas de fusiones y adquisiciones con sistemas de salud a través de posibles joint ventures y adquisiciones, con el objetivo de integrar la atención domiciliaria dentro de ecosistemas de salud más grandes.
La empresa está lanzando el programa Quipt Sales Accelerator para capacitación avanzada en ventas y ampliando su cartera de productos con nuevas ofertas respiratorias. En su Asamblea General Anual, los accionistas aprobaron la reelección de BDO USA como auditor y eligieron a cuatro directores. La junta aprobó la concesión de 425,000 opciones sobre acciones a 2.37 USD por acción y 2,478,753 unidades de acciones restringidas bajo su Plan de Incentivos de Capital 2024.
Quipt Home Medical Corp. (NASDAQ: QIPT)는 2025년 전략적 우선 사항을 발표하며 여러 가지 이니셔티브를 통해 주주 가치를 향상시키는 데 집중하고 있습니다. 이 회사는 플로리다와 앨라배마에서 성공적인 개점을 이어가며 De Novo 지점을 확장하여 유기적 성장을 가속화할 계획이며, 의료 제공자와의 추천 네트워크를 심화할 예정입니다.
주요 전략적 우선 사항에는 회사의 기본에 대한 신뢰를 반영하는 자사주 매입 프로그램을 정상적인 발행자 입찰(NCIB)을 통해 시행하는 것이 포함됩니다. Quipt는 또한 잠재적인 합작 투자 및 인수를 통해 의료 시스템과의 전략적 M&A 기회를 추구하고 있으며, 더 큰 의료 생태계 내에서 가정 기반 치료를 통합하는 것을 목표로 하고 있습니다.
회사는 고급 판매 교육을 위한 Quipt Sales Accelerator 프로그램을 시작하고 새로운 호흡기 제품으로 제품 포트폴리오를 확장하고 있습니다. 연례 총회에서 주주들은 BDO USA의 감사 재임을 승인하고 4명의 이사를 선출했습니다. 이사회는 주당 2.37 USD에 425,000개의 주식 옵션과 2,478,753개의 제한 주식 단위를 2024년 자본 인센티브 계획에 따라 승인했습니다.
Quipt Home Medical Corp. (NASDAQ: QIPT) a annoncé ses priorités stratégiques pour 2025, en se concentrant sur l'amélioration de la valeur pour les actionnaires à travers plusieurs initiatives. L'entreprise prévoit d'accélérer sa croissance organique en développant des emplacements De Novo, suite à des ouvertures réussies en Floride et en Alabama, et en approfondissant les réseaux de référence avec les prestataires de soins de santé.
Les principales priorités stratégiques comprennent la mise en œuvre d'un programme de rachat d'actions par le biais de l'Normal Course Issuer Bid (NCIB), reflétant la confiance dans les fondamentaux de l'entreprise. Quipt poursuit également des opportunités stratégiques de fusions et acquisitions avec des systèmes de santé par le biais de coentreprises et d'acquisitions potentielles, visant à intégrer les soins à domicile au sein de plus grands écosystèmes de santé.
L'entreprise lance le programme Quipt Sales Accelerator pour une formation avancée en vente et élargit son portefeuille de produits avec de nouvelles offres respiratoires. Lors de son Assemblée Générale Annuelle, les actionnaires ont approuvé le renouvellement du mandat de BDO USA en tant qu'auditeur et ont élu quatre administrateurs. Le conseil a approuvé l'attribution de 425 000 options d'achat d'actions à 2,37 USD par action et 2 478 753 unités d'actions restreintes dans le cadre de son Plan d'Incitation en Capital 2024.
Quipt Home Medical Corp. (NASDAQ: QIPT) hat seine strategischen Prioritäten für 2025 bekannt gegeben, die sich auf die Steigerung des Shareholder-Value durch mehrere Initiativen konzentrieren. Das Unternehmen plant, das organische Wachstum durch die Erweiterung von De Novo Standorten zu beschleunigen, nachdem in Florida und Alabama erfolgreiche Eröffnungen stattfanden, und die Überweisungsnetzwerke mit Gesundheitsdienstleistern zu vertiefen.
Zu den wichtigsten strategischen Prioritäten gehört die Implementierung eines Aktienrückkaufprogramms durch ein Normal Course Issuer Bid (NCIB), was das Vertrauen in die Grundlagen des Unternehmens widerspiegelt. Quipt verfolgt auch strategische M&A-Möglichkeiten mit Gesundheitssystemen durch potenzielle Joint Ventures und Übernahmen, mit dem Ziel, die häusliche Pflege in größere Gesundheitsecosysteme zu integrieren.
Das Unternehmen startet das Quipt Sales Accelerator Programm für fortgeschrittene Verkaufsschulungen und erweitert sein Produktportfolio mit neuen Atemtherapieangeboten. Auf der Jahreshauptversammlung genehmigten die Aktionäre die Wiederernennung von BDO USA als Prüfer und wählten vier Direktoren. Der Vorstand genehmigte die Gewährung von 425.000 Aktienoptionen zu 2,37 USD pro Aktie und 2.478.753 Aktienanteilen im Rahmen seines Equity Incentive Plans 2024.
- Implementation of share buyback program through NCIB to enhance shareholder value
- Expansion of De Novo locations following successful openings in Florida and Alabama
- Introduction of new Medicare-approved respiratory device for higher-acuity patients
- Strategic pursuit of healthcare system partnerships and joint ventures for growth
- Need to return to historical organic growth levels indicates current growth underperformance
- Significant equity dilution through 2.9 million new stock options and RSUs
Insights
Quipt Home Medical's 2025 strategic plan represents a calculated shift in their growth and capital allocation strategy. The company is pursuing multiple avenues to enhance shareholder value while acknowledging market perception challenges.
The planned share repurchase program signals management's confidence in the business fundamentals and their belief that shares are undervalued at current levels. With a micro-cap valuation of just
However, investors should carefully weigh this against the simultaneous equity grants of 425,000 stock options and 2,478,753 restricted stock units, which represent potential dilution of approximately
The company's strategic pivot toward healthcare system partnerships represents the most transformative element of their plan. By expanding beyond traditional DME provider acquisitions to pursue joint ventures with healthcare systems, Quipt is attempting to access more predictable patient referral channels and integrate more deeply into the healthcare ecosystem.
The emphasis on returning to "historical levels of organic growth" suggests current growth rates are below the company's past performance, making execution on the De Novo expansion and sales force initiatives particularly important. The lack of specific financial targets or quantifiable metrics makes this more of a directional update than a catalyst-rich announcement.
For a small respiratory care provider competing in a fragmented market, the focused approach on operational efficiency while pursuing targeted expansion appears prudent, though execution risks remain substantial in their healthcare system partnership strategy.
Company Optimizing Capital Allocation Strategy, Expanding De Novo Locations, Deepening Referral Networks, and Advancing a Healthcare System Focused M&A Strategy
CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is pleased to announce its strategic priorities for calendar 2025 and the voting results from its annual general meeting of shareholders held on March 17, 2025 (the “Meeting”) in Sarasota, Florida. The total number of shares represented in person or by proxy at the Meeting was 31,400,043, representing
As it relates to its strategic priorities for 2025, the Company remains committed to returning to historical levels of organic growth, optimizing capital allocation, and building a scalable healthcare ecosystem through innovative M&A, including potential joint venture initiatives.
Accelerating Organic Growth with Focused Expansion Initiatives:
Quipt is diligently working to accelerate organic growth by expanding its De Novo footprint, deepening referral networks, and enhancing operational efficiencies in an effort to sustain strong and consistent margins. Key initiatives include:
- Expansion of De Novo Locations: Following the successful opening of two locations in Florida and Alabama, Quipt plans additional site launches in high-value, strategic markets to strengthen its national presence.
- Deepening Referral Networks: The Company is reinforcing relationships with physicians, hospitals, and healthcare providers in an effort to drive patient acquisition and enhance long-term referral pipelines.
- Sales Force Growth & Training: Quipt is adding new sales representatives in targeted regions while launching the Quipt Sales Accelerator program, an initiative focused on advanced sales education and performance-driven training.
- Operational Efficiencies to Protect Margins: Through optimized intake processes, streamlined sales operations, and improved service delivery, the Company remains committed to preserving strong, consistent margins while delivering exceptional patient care.
- Product Portfolio Expansion: Quipt has been and continues to introduce new respiratory product offerings, including a recently Medicare-approved device, which enhances airway clearance and secretion mobilization, which fits seamlessly into the Company’s strategy of serving higher-acuity respiratory patients.
Capital Allocation Priorities: Plans for Share Buybacks and Potential Strategic M&A with Healthcare Systems
In addition to the Company’s focus on returning to historic levels of organic growth, capital allocation remains a top priority as Quipt intends on taking an aggressive approach to enhancing shareholder value through active share repurchases and by implementing an expanded M&A strategy.
- Share Repurchase Program: The Company plans to execute on its Normal Course Issuer Bid (NCIB) in the coming months, reflecting its confidence in its strong underlying fundamentals and commitment to delivering enhanced value to shareholders. The Company believes that its common shares continue to be undervalued in the market.
- Strategic M&A with Healthcare Systems: Quipt is expanding its historical focus beyond acquiring only traditional DME providers. The Company is currently in active discussions to align with healthcare systems through potential joint venture or strategic acquisition. These opportunities could come with a preferred provider agreement, which presents the Company with significant, untapped growth opportunities to integrate home-based care within larger healthcare ecosystems.
- Building a Scalable Playbook for Health System Partnerships: The Company has begun identifying key healthcare system partners in priority markets, targeting those with established patient bases and aligned objectives, such as reducing hospital readmissions and improving post-acute care. By combining Quipt’s expertise in operational efficiency and clinical excellence with health systems localized patient flow and market knowledge, the Company aims to deepen its geographic reach and provide innovative home healthcare solutions.
- A Replicable Growth Model: The Company’s joint venture strategy will serve as a scalable model for potential future partnerships, in an effort to enable Quipt to expand nationally while strengthening its role as a trusted, value-adding partner in the broader healthcare landscape.
Management Commentary:
“2025 marks a pivotal year for Quipt as we double down on our commitment to augment organic growth and prioritize a disciplined capital allocation strategy while maintaining strong margins,” said Gregory Crawford, CEO and Chairman of Quipt. “We are also dedicated to strategically deploying capital through targeted share repurchases aimed at maximizing shareholder value, while adopting a refined approach to our historical M&A strategy. By aligning with healthcare systems through potential joint ventures and strategic acquisitions, we see a significant and scalable opportunity to accelerate growth and position Quipt as a leader in integrated home-based care. With a focus on improving operational efficiencies, expanding de novo locations into favorable markets, and strengthening our referral pipeline, we are well-positioned to deliver long-term value.”
Annual General Meeting:
Election of Directors
The four candidates nominated for election to the Company’s Board of Directors (the “Board”) and listed in the Company’s management information and proxy circular for the Meeting, were elected by at least a majority of the shareholders present in person or represented by proxy at the Meeting. The voting results are as follows:
| Name | Votes For | % For | Votes Withheld | % Withheld |
| Gregory Crawford | 19,964,556 | 4,800,386 | ||
| Mark Greenberg | 16,068,610 | 8,696,332 | ||
| Kevin Carter | 18,758,930 | 6,006,013 | ||
| Brian Wessel | 18,771,543 | 5,993,400 | ||
The number of broker non-votes for all directors was 6,635,101.
Appointment of Auditors
The Company’s shareholders have approved the re-appointment of BDO USA, P.C. as the auditor of the Company for the fiscal year ended September 30, 2025 and authorized the Board to fix the auditor’s remuneration.
A report of voting results describing each of the matters voted upon at the Meeting has been filed on SEDAR+ under the Company’s issuer profile at www.sedarplus.com.
In addition, the board of directors of the Company has approved the grant of 425,000 stock options and 2,478,753 restricted stock units under its 2024 Equity Incentive Plan to eligible officers, directors and employees and consultants of the Company. The options are exercisable at US
ABOUT QUIPT HOME MEDICAL CORP.
The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient.
Reader Advisories
There can be no assurance that any of the potential acquisitions or joint ventures in the Company’s pipeline or in negotiations will be completed as proposed or at all and no definitive agreements have been executed. Completion of any transaction will be subject to applicable director, shareholder, and regulatory approvals.
Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). The words “may”, “would”, “could”, “should”, "potential”, "will”, "seek”, "intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “outlook”, or the negatives thereof or variations of such words, and similar expressions as they relate to the Company, including: the various strategic priorities of the Company for 2025; the various initiatives the Company has planned to accelerate its organic growth; the Company’s focus on returning to historic levels of organic growth; the Company’s plan to repurchase shares and the timing thereof; the Company’s plan to increase its geographic reach; are intended to identify forward-looking information. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including, without limitation: the Company successfully identifying, negotiating and completing additional acquisitions or joint ventures; operating and other financial metrics maintaining their current trajectories, the Company not being impacted by any further external and unique events like the Medicare 75/25 rate cut and the Change Healthcare cybersecurity incident for the remainder of the calendar year; and the Company not being subject to a material change to it cost structure. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. Examples of such risk factors include, without limitation: risks related to credit, market (including equity, commodity, foreign exchange and interest rate), liquidity, operational (including technology and infrastructure), reputational, insurance, strategic, regulatory, legal, environmental, and capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; a novel business model; dependence on key suppliers; granting of permits and licenses in a highly regulated business; legal proceedings and litigation, including as it relates to the civil investigative demand received from the Department of Justice; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company and a smaller reporting company; the occurrence of natural and unnatural catastrophic events or health epidemics or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with United States Securities and Exchange Commission and available at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statement prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
For further information please visit our website at www.quipthomemedical.com, or contact:
Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
859-300-6455
cole.stevens@myquipt.com
Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
859-300-6455
investorinfo@myquipt.com
FAQ
What are Quipt's (QIPT) main strategic priorities for 2025?
How many shares were represented at Quipt's 2025 Annual General Meeting?
What is Quipt's new share repurchase program for 2025?
What equity incentives did Quipt approve in March 2025?
